TY - JOUR
T1 - No evidence for an involvement of the P38 and JNK mitogen-activated protein in inflammatory bowel diseases
AU - Malamut, Georgia
AU - Cabane, Candice
AU - Dubuquoy, Laurent
AU - Malapel, Mathilde
AU - Dérijard, Benoit
AU - Gay, Jérôme
AU - Tamboli, Cyrus
AU - Colombel, Jean Frédéric
AU - Desreumaux, Pierre
N1 - Funding Information:
Acknowledgment We enjoyed the support of grant from the Fondation pour la Recherche Médicale (FRM).
PY - 2006/8
Y1 - 2006/8
N2 - Involvement of mitogen-activated protein (MAPK) in inflammatory bowel disease (IBD) remains enigmatic. We sought to evaluate the expression and activity of p38 and JNK MAPK in IBD and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis; and the effects of a p38 inhibitor, SB203580, in TNBS colitis. P 38 and JNK were quantified in colonic mucosa of 28 IBD patients and 19 controls and in 77 TNBS or control mice treated or not with SB203580. Colitis severity was assessed by survival, macroscopic and microscopic scoring, and molecular markers. Expression and activity of p38 and JNK were similar in IBD patients and controls and not modified by inflammation. In mice, p38 and JNK expression or activity did not increase following the induction of colitis. SB203580 decreased the p38 activity but displayed no clinical nor biological therapeutic effect. In conclusion, these results minimize the role of p38 and JNK in inflammatory colitis and the interest of p38 as a therapeutic target in IBD.
AB - Involvement of mitogen-activated protein (MAPK) in inflammatory bowel disease (IBD) remains enigmatic. We sought to evaluate the expression and activity of p38 and JNK MAPK in IBD and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis; and the effects of a p38 inhibitor, SB203580, in TNBS colitis. P 38 and JNK were quantified in colonic mucosa of 28 IBD patients and 19 controls and in 77 TNBS or control mice treated or not with SB203580. Colitis severity was assessed by survival, macroscopic and microscopic scoring, and molecular markers. Expression and activity of p38 and JNK were similar in IBD patients and controls and not modified by inflammation. In mice, p38 and JNK expression or activity did not increase following the induction of colitis. SB203580 decreased the p38 activity but displayed no clinical nor biological therapeutic effect. In conclusion, these results minimize the role of p38 and JNK in inflammatory colitis and the interest of p38 as a therapeutic target in IBD.
KW - Colitis
KW - Inflammatory bowel disease
KW - Intestinal inflammation
KW - JNK MAPK
KW - P38 MAPK
KW - SB203580
KW - TNBS
UR - http://www.scopus.com/inward/record.url?scp=33748164488&partnerID=8YFLogxK
U2 - 10.1007/s10620-006-9116-2
DO - 10.1007/s10620-006-9116-2
M3 - Article
C2 - 16838116
AN - SCOPUS:33748164488
SN - 0163-2116
VL - 51
SP - 1443
EP - 1453
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 8
ER -